Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis

Clinical Drug Investigation

Volumn 26, Issue 8, 2006, Pages 469-479

  Rolla, Valeria Cavalcanti ^a   Vieira, Maria A Da Silva ^b   Pinto, Douglas Pereira ^a   Lourenço, Maria C ^a   Jesus, Carlos Da Silva De ^c   Morgado, Mariza Gonçalves ^c   Filho, Milton Ferreira ^a   Werneck Barroso, Eduardo ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEPATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; MALE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RASH; STEADY STATE; TASTE DISORDER; TUBERCULOSIS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BISEXUALITY; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOMOSEXUALITY; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; METABOLIC CLEARANCE RATE; RIFAMPIN; RITONAVIR; SAQUINAVIR; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 33747306726     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626080-00005     Document Type: Article

References (23)

1. Pan American Health Organization. Health situation in the Americas: basic indicators 2004 [online]. Available from URL: http://www.paho.org/english/dd/ aids/bi-brochure2004 [Accessed 2006 Feb 16]
2. Gadelha A, Accácio N, Costa RLB, et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 2002; 44 (4): 179-86
3. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367-73
4. Strayhorn VA, Baciewich AM, Self TH. Update on rifampin drug interaction, III. Arch Intern Med 1997; 157: 2453-8
5. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug to drug interaction in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000; 30 Suppl. 2: s123-9
6. Veldkamp AI, Hoetelmans RM, Beijnen JH, et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586
7. Ministério da Saúde, Programa de DST/Aids. Brazil. Programa Nacional de Controle de Doenças Sexualmente Transmissíveis/Aids 2001 [online]. Available from URL: http://www.aids.gov.br [Accessed 2006 Jul 12]
8. II Consenso Brasileiro de tuberculose: Diretrizes Brasileiras para tuberculose 2004: Jornal Brasileiro de Pneumologia 2004; 30 (S1)
9. Grinsztejn B, Fandinho FCO, Veloso VG, et al. Mycobacteremia in patients with the acquired immunodeficiency syndrome. Arch Intern Med 1997; 157 (20): 2359-63
10. The AIDS Clinical Trials Group (ACTG). Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health, August 1992 [online]. Available from URL: http://aactg.s-3.com. (R01-00100) [Accessed 2006 Jul 12]
11. MMWR updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors, version 1.20.2004. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for using antiretroviral agents among HIV-infected adults and adolescents [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/00052295. htm [Accessed 2006 Jul 12].
12. Ministerio da Saude, Programa da DST/Aids. 2000. Brasil. Programa Nacional de Controle de Doenças Sexualmente Transmissíveis/Aids Min. Saúde. 22/09/2000
13. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach, 2003 [online]. Available from URL: http://www.who.int/hiv/pub/prev_care/en/ arvrevision2003en.pdf [Accessed 2006 Jul 12]
14. La Porte CJL, Colbers EPH, Berts r, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-60
15. Burman WJ, Galiicano K, Peloquim C. Therapeutic implication of drug interaction in the treatment of HIV and tuberculosis. Clin Infect Dis 1999; 28: 419-29
16. Berning SE, Huitt GA, Iseman MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817-8
17. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-9
18. Lea AP, Faulds D. Ritonavir. Drugs 1996; 52 (4): 541-6
19. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir or efavirenz. AIDS 2001; 15: 1679-86
20. Moreno S, Podzamczer D, Blásques R, et al. Treatment of tuberculosis in HIV infected patient: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampicin. AIDS 2001; 15 (9): 1185-7
21. Ribera E, Azuaje C, Lopes RM, et al. Once daily regimen of saquinavir ritonavir didanosine and lamivudine in HIV infected patients with standard tuberculosis therapy. J Acquir Immune Defic Syndr 2005; 40 (3): 317-23
22. Data on file F Hoffmann-la Roche Ltd. Preliminary report study bp18180: effect of multiple dose rifampicin on the steady-state pharmacokinetics of saquinavir combined with low dose ritonavir and vice versa in healthy volunteers; 2005 Mar
23. Witvrouw M, Pannecouque C, Desmyter J, et al. In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Res 2000; 46: 215-21